LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Pacira Pharmaceuticals Inc-DE

Cerrado

SectorSalud

23.43 -1.18

Resumen

Variación precio

24h

Actual

Mínimo

23.21

Máximo

23.94

Métricas clave

By Trading Economics

Ingresos

-11M

4.8M

Ventas

-18M

169M

P/B

Media del Sector

11.23

50.291

BPA

0.62

Margen de beneficio

2.849

Empleados

788

EBITDA

-17M

34M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+73.98% upside

Dividendos

By Dow Jones

Próximas Ganancias

29 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-88M

1.1B

Apertura anterior

24.61

Cierre anterior

23.43

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

162 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Pacira Pharmaceuticals Inc-DE Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

7 abr 2025, 23:45 UTC

Acciones populares

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

2 jul 2024, 16:22 UTC

Principales Movimientos del Mercado

Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic

Comparación entre iguales

Cambio de precio

Pacira Pharmaceuticals Inc-DE Esperado

Precio Objetivo

By TipRanks

73.98% repunte

Estimación a 12 meses

Media 41.25 USD  73.98%

Máximo 65 USD

Mínimo 26 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pacira Pharmaceuticals Inc-DE Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

3

Comprar

3

Mantener

1

Vender

Puntuación técnica

By Trading Central

24.83 / 26.38Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

162 / 380 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.